Auron Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $48M
Overview
Developing differentiation therapies that reprogram cancer cells to treat resistant tumors.
Oncology
Technology Platform
The GENESIS platform uses functional genomics to identify master regulator targets that control tumor cell state, enabling the development of differentiation therapies.
Funding History
1Total raised:$48M
Venture$48M
Opportunities
Potential to create durable responses in hematologic and solid tumors by addressing cancer stem cells and drug-resistant persister cells.
Risk Factors
Unproven clinical mechanism with risk of unpredictable biological effects and potential difficulty in measuring differentiation endpoints in trials.
Competitive Landscape
Operates in a nascent field of differentiation therapy, with few direct competitors, but must prove clinical feasibility against established modalities.